EGFR and non-small cell lung carcinoma: The intracranial ORR was significantly higher in the icotinib arm than in the whole brain irradiation plus chemotherapy arm (67.1% vs 40.9% P = 0.001), as was the ORR (55.0% vs 11.1%; P = 0.001), indicating that icotinib is a feasible treatment option for patients with EGFR-mutant NSCLC with brain metastasis [7].